The large-scale healthcare industry requires high-performance pharmaceutical machinery.

With the end of China’s one-child policy, the proportion of an aging population will continue to rise for a long time to come. Those just entering old age are more concerned about their health issues than their predecessors and are actively taking steps to improve it. In an era when the primary focus was on survival, physical health was little more than a luxury. Today, the situation has vastly improved. Compared with their elders, the new generation of middle-aged and elderly people not only pay greater attention to their physical well-being but also enjoy stronger economic means. The resulting surge in production capacity—and the accompanying growth of the large-scale healthcare industry—is unmistakable. Another troubling issue is that the physical condition of Chinese people is far from optimistic. Looking at children’s education, we can see that promoting robust physical health seems at odds with the demands of exam-oriented education. Teenagers of school age are subjected to exams and homework at all levels. After spending most of their day studying, my sleep has been severely curtailed—I can only play golf and occasionally swim. A wealth of data indicates that the physical condition of young Chinese people is indeed cause for concern. Some young people with weak physical foundations have developed many unhealthy habits. According to one survey, taking smoking as an example, the number of smokers in China is aging and becoming increasingly female. China has now become the world’s largest producer of tobacco—and also its biggest consumer. Moreover, an increasing number of teenagers are turning away from video games, especially left-behind children whose parents work in cities. The situation in workplaces is equally discouraging. Compared with those in developed countries in Europe and the U.S., Chinese workers face longer overtime hours due to structural imbalances and low productivity—not only in factories and construction sites, but even in office environments. Most restaurants and entertainment venues are bustling with business activities. Even those attending banquets feel overwhelmed; under performance pressure, many salespeople are forced to work until late at night—and some have already fallen ill. Rising housing prices are placing even greater survival pressures on young people from rural or less-developed areas. To afford down payments exceeding 50% of their salaries and monthly mortgage payments, those who have never enjoyed good physical or mental health since childhood—and especially only children—will naturally experience more physical and psychological problems. The most telling statistic is the declining success rate of conception among people of the right reproductive age. China, which has just stepped onto the threshold of modernization, is now facing the overuse and depletion of its national health resources. As suppliers of pharmaceuticals and healthcare equipment, industry players are benefiting from the rapid growth of the healthcare sector—a development that is both encouraging and heartbreaking. As GMP policies drive massive investments in pharmaceutical equipment, the issues discussed in this article are increasingly becoming a pressing need for the expansion of the healthcare industry. The growth in market demand has sharply contrasted with the industry’s supply capacity, and this gap is now aligning with the country’s overall strategic objectives. The situation is strikingly similar across the board: whether it’s pharmaceuticals and healthcare products or upstream equipment manufacturers, there’s an overabundance of low-end products alongside a shortage of high-quality ones. Promoting supply-side structural reform and steadfastly adjusting production capacity have thus become urgent challenges facing the broader healthcare industry. The vast majority of Western medicines sold domestically are generic drugs. Many of these generics on the market are wasting resources, suffering from overcapacity, low profits, and poor efficacy. Since 2016, China’s National Medical Products Administration has implemented a consistency evaluation program in the pharmaceutical industry. Industry leaders with high-quality resources have continuously passed the consistency evaluation, gaining a first-mover advantage. Meanwhile, these companies have embarked on another round of large-scale mergers and acquisitions. Generic drug varieties that have passed the consistency evaluation are also expanding production capacity and securing major orders. On the product strategy front, companies are continuing to increase R&D investment while simultaneously acquiring more advanced and intelligent production lines, further boosting efficiency and cutting manufacturing costs. The domestic pharmaceutical machinery market mirrors the downstream pharmaceutical market: foreign imported products command extremely high prices, and high-end domestic products remain scarce. Yet, the market is flooded with crude, low-grade products.